Gary Nachman
Recent Articles
Asceniv Growth, Margin Expansion, and Pipeline Optionality Drive Price Target 04/23/2026
Canaccord Genuity initiates coverage of ADMA Biologics Inc. (ADMA:NASDAQ), citing Asceniv's differentiated hyperimmune IVIG profile, accelerating margins from yield enhancement, and an underappreciated pipeline.
Due to permission requirements, not all quotes are shown.
